Mandate

Vinge has advised Tobii AB (publ) in connection with its rights issue

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary shares which will provide Tobii with issue proceeds of approximately SEK 301 million before deduction of transaction costs.

The new ordinary shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 15 April 2024. Tobii develops technology within eye tracking and attention computing which understands human attention and intent. Tobii’s eye tracking solutions are used by thousands of enterprises, universities and research institutes around the globe. The company's ordinary shares are listed on Nasdaq Stockholm.

 

Vinge’s team consisted primarily of Jesper Schönbeck, Rikard Lindahl, Amanda Knutsson, Joel Magnusson, Oskar Nilsson, Lorin Arabi, Elias Kröger, Lovisa Jonassen och William Carlberg Johansson.

Related

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026